The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

Treatment Updates in Early Stage NSCLC - Advances in Thoracic Oncolo…

Total Health

J. Porter

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

2024 ASCO® Annual Meeting Insights Hub

L. Raez

Year in Review: Lung Cancer

Balazs Halmos

Treatment Updates in Advanced and Metastatic NSCLC - Advances in Tho…

Total Health

J. Porter

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics

Springer Healthcare IME

S. Peters

An Update on Lung Cancer Targeted Therapies: The Evolution of Person…

University of Miami Sylvester Comprehensive Cancer Center

E. Rodriguez